Pfizer and AstraZeneca

AstraZeneca: If Schroders, the latest to join the chorus, stated out loud that AstraZeneca board was silly to reject 55-a-share one would understand. It would be expressing a clear and straightforward opinion, according to The Guardian. But there was plenty of engagement with Pfizer that what the talks at the weekend were all about. For better or worse, no deal was possible. AstraZeneca wanted at least 58.85 and Pfizer wouldn't go that high and What do these "disappointed" fund managers calling for more "engagement" between AstraZeneca and Pfizer actually want? But that not what Schroders is saying. It merely thinks Pfizer drew a "premature end" to negotiations by declaring 55 to be a final proposal and it wants to "encourage the AstraZeneca management to recommence their engagement with Pfizer." (news.financializer.com). As reported in the news.